Statewide burden of cancer attributable to alcohol use in the United States in the last three decades, projections of deaths to 2040: A benchmarking study.

Authors

null

Geethika Potluri

Duke University, Durham, NC

Geethika Potluri , Sri Usha Jeevani Obulareddy , Himanshu Bharatkumar Koyani , Dhruvkumar Gadhiya , Keethanshan Markandu , Kavya Maddineni , Victor O Adedara , Anusha Parisapogu , Hardik Dineshbhai Desai , Rushin Patel , Ummul Barakat Zakia , Colleen Bramwell

Organizations

Duke University, Durham, NC, Associate Professor Division of Hematology/Oncology Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, Sterling Hospitals, Rajkot, Gujarat, India, St. Luke's University Health Network Anderson Campus, Easton, PA, Penn State Hershey, Hershey, PA, Kent State University, Kent, OH, St. George's University School of Medicine, True Blue, Grenada, Mayo Clinic, Rochester, MN, Gujarat Adani Institute of Medical Science, Bhuj, Ahmedabad, India, Department of Internal Medicine, Community Hospital of San Bernardino, San Bernardino, CA, St. Luke's University Health, Anderson Campus, Easton, PA, St. Luke's University Health Network, Easton, PA

Research Funding

No funding sources reported

Background: Cancer stands as the 2nd leading cause of deaths and disability in the United States (US), and among the numerous contributing factors, modifiable risk factors play a significant role in exacerbating this burden. Within the spectrum of cancers, alcohol consumption ranks as the second leading attributable cause of death, as per the Global Burden of Disease Cancer Attributable Risk Factor Study. Methods: Employing the GBD protocol, we conducted an estimation of deaths, disability-adjusted life years (DALYs) attributable to cancer caused by alcohol consumption in the US. This comprehensive analysis was stratified by age, gender, year, and geographical location throughout the US, from 1990 to 2019. To project future trends, we utilized time-series regression techniques to forecast deaths until the year 2040. Results: The total number of cancer-related deaths in the US surged from 19,898 (95%UI: 17,791-22,149) in 1990 to 34,455 (30,542-38,388) in 2019. Concurrently, DALYs increased from 532,533 (480,249-586,646) in 1990 to 854,351 (764,549-949,378) in 2019, and YLLs rose from 501,639 (452,446- 554,400) in 1990 to 802,493 (717,123-891,789) in 2019. The highest annual percentage change (APC) in ASR for mortality was observed in West Virginia, with a 32% increase, followed by Tennessee at 27%. Conversely, the District of Columbia witnessed the most significant decrease, with a 30% reduction from 1990 to 2019. In terms of DALYs rates, the highest increases were observed in West Virginia (27%) and Oklahoma (21%). Males bore a greater overall burden compared to females, with an APC in deaths of 97% vs 40% and an APC in DALYs of 87% vs 26%. The highest number of deaths occurred in the 60-64 age group, with 5,228 cases in 2019, while DALYs reached 154,034 in the same year. Projections indicate that the total number of deaths is expected to increase by 49,230 by the year 2040. Conclusions: In 2019, cancer-related deaths attributed to alcohol use represented 4.42% of all cancer mortality cases. From both a public health and clinician perspective, the study's results highlight the urgent need for comprehensive strategies to address the growing burden of cancer associated with alcohol use. Efforts should focus on prevention, early intervention, and support for individuals struggling with alcohol-related cancer risks.

Cancer attributable to Alcohol UseDeathsDALYs
19902019APC (%)19902019APC (%)
Breast cancer4448.154852314030615534211
Nasopharynx cancer436.652921139461579813
Liver cancer1877.2739529444370177320300
Lip and oral cavity cancer2412.8339041660298401227
Other pharynx cancer876146367249884017461
Esophageal cancer2945.960931077474214172390
Larynx cancer949.5120026257603049918
Colon and rectum cancer5951.588975014239020948147

APC: Annual Percentage of change, DALYs: Disability adjusted life years.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Genetics

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Etiology/Epidemiology

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 10575)

DOI

10.1200/JCO.2024.42.16_suppl.10575

Abstract #

10575

Poster Bd #

102

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Quality Care Symposium

Association of disability with long-term noncompliance of breast cancer screening.

First Author: Hyo Jung Tak

Abstract

2023 ASCO Annual Meeting

Risk factors of early liver metastasis in patients with breast cancer.

First Author: Minxue Zhu

First Author: Marlid Cruz Ramos